Slow Human Immunodeficiency Virus (HIV) Infectivity Correlated with Low HIV Coreceptor Levels

CYNTHIA L. BRISTOW*

Department of Pathology and Laboratory Medicine, University of North Carolina—Chapel Hill,
Chapel Hill, North Carolina 27514

Received 26 February 2001/Returned for modification 23 April 2001/Accepted 24 May 2001

The absolute number of CD4+ lymphocytes in blood is prognostic for disease progression, yet the cell surface density of CD4 receptors or chemokine receptors on a single cell has not previously been found to be predictive of human immunodeficiency virus (HIV) infectivity outcome. It has recently been shown that human leukocyte elastase (HLE) and its ligand α1 proteinase inhibitor (α1PI; α1 antitrypsin) act as HIV fusion cofactors. The present study shows that decreased HIV infectivity is significantly correlated with decreased cell surface density of HLE but not with decreased CD4 nor chemokine receptors. In vitro HIV infectivity outcome in this study was predicted by the surface density of HLE on mononuclear phagocytes but not on lymphocytes. The set point HLE surface density was in part determined by α1PI. Decreased circulating α1PI was correlated with increased cell surface HLE and with increased HIV infectivity. The correlation of HIV infectivity outcome with surface HLE and circulating α1PI supports the utility of these HIV cofactors in diagnostic analysis and therapeutic intervention.

We previously demonstrated that cell surface human leukocyte elastase (HLE) specifically and reversibly binds the HIV fusion domain (Bristow et al. [3]). We have recently found that human immunodeficiency virus (HIV) preferentially binds to copatches of HLE, CD4, and chemokine receptors (C. L. Bristow et al., unpublished data). HIV receptors were found to copatch in response to α1 proteinase inhibitor (α1PI) potently explaining the requirement for α1PI during HIV entry. These studies led to the hypothesis that α1PI might impact HIV disease progression. Indeed, in a study of HIV-seropositive patients, we recently found that decreased circulating α1PI is significantly correlated with decreased viral load (3a). The prognostic value of measuring α1PI was found to be comparable to measuring CD4 and considerably better than measuring CD4+ lymphocytes, to measuring CD4 and considerably better than measuring CD4+ lymphocytes.

Materials and Methods

Subjects. Blood was collected from eight different HIV-seronegative healthy volunteers after we obtained informed consent. Subjects were selected to represent a range of α1PI concentrations in serum. All subjects were normally healthy; however, the female counterpart from a pair of siblings homozygous for the α1PI-deficient genotype P402Z (2) was included for comparison despite her history of systemic lupus erythematosus.

Quantitation of α1M and α1PI. Sera were measured at the time of collection for α1M, as well as for active- and inactive-α1PI concentrations. Methods for quantitating active and total α1PI have been described elsewhere (2). Active α1M and α1PI concentrations were determined by elastase inhibitory capacity. Total α1PI was determined by enzyme-linked immunosorbent assay. Inactive α1PI was expressed as the difference between total α1PI and active α1PI.

Active-site standardization of exogenous α1PI. Active-site standardization was performed as previously described (2). One mole of active-site titrizable porcine pancreatic elastase, type 1 (EC 3.4.21.36; Sigma) was found to saturate 3.06 moles α1PI (Sigma), suggesting that this preparation was 32.7% active.

In vitro HIV infectivity of mononuclear cells. PBMC were isolated from whole blood collected in tubes containing ACD (Becton Dickinson, San Jose, Calif.). Three primary non-syncytium-inducing HIV type 1 (HIV-1) clinical isolates were generously provided by the Retrovirology Core Laboratory, UNC-Chapel Hill. In vitro infectivity outcome was determined by quantitating p24 accumulation or reverse transcriptase (RT) activity as previously described (3, 5). Isolated PBMC were resuspended and maintained in the wells of a 96-well tissue culture plate at 2 × 10^6 cells/ml in RPMI 1640 containing 20% autologous serum and 10% interleukin-2 (Cellular Products, Buffalo, N.Y.). PBMC in 100 μl in autologous medium were stimulated by the addition of 5 μg of phytohemagglutinin (PHA; Sigma) per ml for 3 days at 37°C in humidified 5% CO2. Cells were washed and resuspended in fresh autologous medium containing various concentrations of exogenous active-site standardized α1PI (Sigma).

For the determination of RT activity, PHA-stimulated PBMC were incubated with a 2 × 10^−8 M tissue culture infective dose (TCID50) of HIV-1 for 2 h at 37°C and 5% CO2. Cells were subsequently washed three times, resuspended, and cultured in fresh autologous medium containing matching exogenous α1PI. Aliquots of 50 μl of culture supernatants were collected and replaced with fresh autologous medium containing matched exogenous α1PI every other day on days.
RESULTS AND DISCUSSION

Influence of α1PI on HIV-1 produced by PBMC infected in vitro. To determine whether α1PI might influence HIV infectivity, healthy volunteers were selected to represent a range of circulating α1PI levels (Table 1). PBMC from these individuals were infected in vitro using three concentrations of a non-syncytium-inducing clinical isolate of HIV-1. PBMC were maintained at all times in autologous serum containing various α1PI concentrations of exogenous α1PI, RT activity was negligible regardless of the cell source (Fig. 1) or viral inoculum (data not shown). However, in the presence of exogenous α1PI, RT activity was increased in a dose-dependent manner, with the highest RT activity observed at the highest concentration of α1PI. These results suggest that α1PI might influence HIV infectivity by interfering with the entry of HIV-1 into the target cells.

2 through 8. Culture supernatants were stored at ~80°C for analysis of the RT activity.

For the determination of the p24 accumulation, PHA-stimulated PBMC were incubated with 10 or 40 TCID50 of HIV-1 for 2 h at 37°C and 5% CO2. Cells were subsequently washed three times and resuspended in fresh autologous medium and cultured at 3 x 10^6 cells/l.5 ml/well. Aliquots of 225 µl were removed each day for p24 determination (without the replacement of fresh media) on days 2 through 7. Cell counts and viability were determined at the final time point. In the uninfected cell controls, (1.68 ± 0.36) x 10^6 PBMC were 96% ± 7% viable. In the infected cells, (2.39 ± 0.37) x 10^6 PBMC were 88% ± 3% viable.

Immunofluorescent staining and flow cytometric analysis. Three-parameter flow cytometric analysis using direct immunofluorescent staining of whole blood was performed on a FACScan flow cytometer (Becton Dickinson) using fluorescein isothiocyanate (FITC), phycoerythrin (PE), and peridinin chlorophyll protein (PerCP) by using methods recommended by the manufacturer. To detect chemokine receptors, blood was stained simultaneously in a single step with three monoclonal antibodies which included (i) anti-CD14-FITC, anti-CCR5-PE, and anti-CD4-PerCP (PharMingen); or (ii) anti-CD14-FITC, anti-CXCR4-PE, and anti-CD4-PerCP (PharMingen); or (iii) anti-CD14-FITC, immunoglobulin G2a (IgG2a)-PE, and anti-CD4-PerCP (PharMingen). To detect cell surface HLE, blood was stained stepwise with three antibodies, including polyclonal sheep anti-HLE-FITC (Biodesign, Inc., Kennebunkport, Maine), monoclonal anti-CXCR4-PE (PharMingen), and monoclonal anti-CD4-PerCP (Becton Dickinson). The isotype-matched controls were IgG2a-PE, IgG1-PerCP, or nonspecific IgG-FITC. Blood was washed in 2 ml of phosphate-buffered saline between each staining step.

For each analysis, 30,000 events were acquired. List mode multiparameter data files were analyzed using CellQuest Software (Becton Dickinson). Because the fraction of CD4+ lymphocytes and CD4+ mononuclear phagocytes varied considerably between individuals, the fluorescence intensity was normalized to the CD4+ cells in the gate containing either lymphocytes or mononuclear phagocytes. The relative geometric mean fluorescence intensities (RFI) were determined as geometric mean fluorescence intensity (MFI) relative to CD4 = geometric MFI of coreceptor/ geometric MFI of CD4.

FIG. 1. In vitro HIV infectivity of PBMC in the presence of exogenous α1PI. (a) Infection outcome using a non-syncytium-inducing clinical isolate of HIV-1 was determined in duplicate by measuring the RT activity produced by PBMC from subjects 1 (■), 2 (▲), 3 (▼), 4 (●), 5 (●), and 6 (●), represented in Table 1 in the absence or presence of 3 or 30 µM exogenous α1PI in autologous serum. Mean values are depicted. (b) On day 8, the RT activity in the culture supernatants increased as the exogenous α1PI concentration increased.

TABLE 1. Coreceptor levels and circulating α1PI and α1M in HIV-seronegative volunteers

| Subject | Sex | α1M concn (µM) | α1PI concn (µM) | Lymphocyte (MFI) | Mononuclear phagocytes (MFI) |
|---------|-----|----------------|-----------------|------------------|-----------------------------|
|         |     |                |                 |                  | CD4+ | CCR5+ | CXCR4+ | HLE+ | CD4+ | CCR5+ | CXCR4+ | HLE+ |
| 1       | M   | 5.65           | 1.9             | 105              | 31              | 24              | 176              |       | 16    | 23    | 39    | 257  |
| 2       | F   | 5.57           | 3.0             | 98               | 25              | 101             | 190              |       | 25    | 32    | 112   | 341  |
| 3       | F   | 5.12           | 11.0            | 109              | 11              | 32              | 165              |       | 19    | 17    | 42    | 248  |
| 4       | M   | 3.53           | 34.0            | 114              | 17              | 71              | 245              |       | 14    | 21    | 50    | 167  |
| 5       | M   | 3.34           | 42.4            | 97               | 21              | 109             | 178              |       | 32    | 43    | 63    | 325  |
| 6       | F   | 2.26           | 61.2            | 121              | 13              | 50              | 178              |       | 19    | 15    | 19    | 177  |
| 7       | F   | 3.50           | 13.7            | ND               | ND              | ND              | ND               |       | ND    | ND    | ND    | ND   |
| 8       | M   | 5.57           | 39.5            | ND               | ND              | ND              | ND               |       | ND    | ND    | ND    | ND   |

* M, male; F, female.

b Active concentration determined by elastase inhibition.

c Geometric mean fluorescence was detected by flow cytometry. Lymphocytes identified by forward and side scatter were gated to represent the CD4+ population. Mononuclear phagocytes identified by forward and side scatter were gated to represent the CD4+ CD14+ population. CCR5, CXCR4, and HLE are represented as the geometric mean fluorescence intensity (MFI) within gated cells. ND, not determined.
activity was detected in PBMC from three subjects. These three subjects were found to constitutively manifest deficient circulating α<sub>1</sub>PI. New virus increased as circulating α<sub>1</sub>PI decreased (\( r^2 = 0.95, P < 0.001 \)). In contrast, new virus increased in a manner dependent upon increasing active α<sub>1</sub>PI tissue culture concentration. These results suggest the hypothesis that cells conditioned in vivo by increased concentrations of α<sub>1</sub>PI are less sensitive and less responsive to α<sub>1</sub>PI in tissue culture, perhaps due to downregulation of an HIV coreceptor. Two of the subjects studied are known to be homozygous for the PI<sub>ZZ</sub> genotype (2). The phenotype of the third subject is not known; however, the α<sub>1</sub>PI levels (11 μM) in this subject are inconsistent with PI<sub>ZZ</sub>. This suggests that α<sub>1</sub>PI levels, but not the genotype producing α<sub>1</sub>PI deficiency, determine HIV outcome.

To further investigate the influence of circulating α<sub>1</sub>PI on HIV infectivity of PBMC, p24 production was determined in cells infected in vitro in autologous serum. Active levels of circulating α<sub>1</sub>PI were again found to be related to p24 production; the lower the concentration of α<sub>1</sub>PI in serum, the greater the p24 produced (Fig. 2). That p24 produced by cells infected with 40 TCID<sub>50</sub> was proportionally greater than by cells infected with 10 TCID<sub>50</sub> suggests that infectious dose was a primary determinant in p24 synthesis. Because p24 accumulates in tissue culture supernatants under these conditions, comparing HIV produced by PBMC from these individuals was facilitated by determining the rate of accumulation. It was found that the levels of α<sub>1</sub>PI were significantly correlated with the rate of p24 accumulation prior to day 4 when cells were exposed to either infectious dose. In contrast, the rate of p24 accumulation after day 4 was equivalent regardless of the PBMC source or individual α<sub>1</sub>PI concentration in serum. These results are consistent with previous evidence using homogeneous cell populations, suggesting that once an infection is initiated in vitro, subsequent infectious cycles are kinetically indistinguishable (4). That the rate of p24 accumulation prior to day 4 maintained the rank order of all five individuals at either infectious dose suggests that p24 synthesis was not limited by the capacity of the infected cells for new protein synthesis but was limited by the number of initially infected cells in a manner determined by the infectious dose. In vitro HIV infectivity of PBMC is notoriously variable; however, the consistency of results in three independent experiments with eight individuals representing a range of α<sub>1</sub>PI concentrations in serum supports the hypothesis that α<sub>1</sub>PI is a physiologically relevant cofactor for HIV. One of the individuals in this study has been found routinely to have normal active α<sub>1</sub>PI levels (40 μM) but at the time of the current study exhibited an unusually low level (13.7 μM). This further supports the conclusion that it is the α<sub>1</sub>PI level, and not the α<sub>1</sub>PI phenotype, which influences HIV outcome.

It has previously been reported that α<sub>1</sub>PI inhibits HIV infectivity (6). Evidence presented here suggests that α<sub>1</sub>PI facilitates HIV infectivity. We have recently found that α<sub>1</sub>PI produces a short-lived window for HIV entry (unpublished results). HIV coreceptors are initially disperse, are stimulated to copatch within 15 min of exposure of cells to α<sub>1</sub>PI, and then pinch off from the plasma membrane following a period of 30 to 60 min, forming small platelet-like transitory cytoplasmic bodies (SPTBalls). The corresponding disappearance of HIV infectivity and the appearance of SPTBalls suggests the possibility that SPTBalls may serve to uncouple cellular responsiveness including HIV entry.

**Influence of circulating α<sub>1</sub>PI on HIV coreceptor density.**

The relationship between infectivity and coreceptor densities was compared using blood collected from the same six volunteers as those for which RT activity was measured. We have observed that cell surface HLE on promonocytic cells appears to be increased when the cells are interacted with antibodies specific for CD4 first and specific for HLE secondarily and then decreased when the order of antibody addition is reversed (C. L. Bristow, unpublished data). When blood was first reacted with anti-HLE and secondarily with anti-CD4 or antibodies specific for CXCR4 or CCR5, HLE density was negligible on CD4<sup>+</sup> lymphocytes or CD4<sup>+</sup>CD14<sup>+</sup> mononuclear phagocytes (Fig. 3). When blood was reacted with antibodies in the reverse order, considerable levels of HLE were detected on both CD4<sup>+</sup> lymphocytes and CD4<sup>+</sup>CD14<sup>+</sup> mononuclear phagocytes. In contrast, the order of coreceptor ligation had no influence on the fluorescence intensities of CD4, CD14, CCR5, or CXCR4 (data not shown). These results suggest a dynamic
results, when coreceptors were expressed as the fluorescence intensity relative to HLE, increased RT activity was found to be related to CD4 on CD4+ CD14+ mononuclear phagocytes but not to either CXCR4 or CCR5 (data not shown). In this case, increased numbers of CD4 molecules associated with each HLE molecule resulted in decreased RT activity. These results support the hypothesis that, although all coreceptors may participate during HIV entry, the ratio of cell surface of HLE and CD4, but not CXCR4 nor CCR5, is determinant during HIV infectivity outcome.

As was found for RT activity, decreased cell surface HLE relative to CD4 on CD4+ CD14+ mononuclear phagocytes was correlated with increased circulating α1,PI ($r^2 = 0.95, P = 0.0008$). Neither circulating α1,PI, nor α2, M was related to CXCR4 or CCR5 relative to CD4 on CD4+ CD14+ mononuclear phagocytes or any coreceptors on CD4+ lymphocytes.
These results suggest that circulating $\alpha_1$PI may modulate cell surface HLE on peripheral blood mononuclear phagocytes, thereby diminishing the number of HIV-responsive cells.

Although tropism was not addressed in the present study, the relationship between RT activity and coreceptors on mononuclear phagocytes suggests that the viral isolate used may have been tropic for these cells. The dynamic relationship between coreceptors on PBMC may not be consonant with their relationship in lymph nodes or in tissue where differentiation pathways are subject to the local environment; however, these results suggest new targets for therapeutic intervention which could potentially prolong or prevent the onset of the symptomatic clinical status and AIDS.

ACKNOWLEDGMENTS

I thank D. Irlbeck and A. Cachefeiro for technical assistance; J. Mantell for critically reviewing the manuscript; and P. Davis, T. Gee, R. Arnold, G. Thompson, W. Ambrose, C. Vanderwall, R. Kellam, and C. Broderius for the gracious contributions and support which made this work possible.

This research was supported by the UNC Center for AIDS Research grant and by a grant from the University Research Council of the University of North Carolina–Chapel Hill.

REFERENCES

1. Berninger, R. W. 1986. Alpha 1-antitrypsin. J. Med. 16:23–99.
2. Bristow, C. L., F. di Meo, and R. R. Arnold. 1998. Specific activity of $\alpha_1$ proteinase inhibitor and $\alpha_2$ macroglobulin in human serum: application to insulin-dependent diabetes mellitus. J. Clin. Immunol. Immunopathol. 89: 247–259.
3. Bristow, C. L., S. A. Fiscus, P. M. Flood, and R. R. Arnold. 1995. Inhibition of HIV-1 by modification of a host membrane protease. Int. Immunol. 7:239–249.
3a. Bristow, C. L., H. Patel, and R. R. Arnold. 2001. Self antigen prognostic for human immunodeficiency virus disease progression. Clin. Diagn. Lab. Immunol. 8:937–942.
4. Dimitrov, D. S., R. L. Willey, H. Sato, L. J. Chang, R. Blumenthal, and M. A. Martin. 1993. Quantitation of human immunodeficiency virus type 1 infection kinetics. J. Virol. 67:2182–2190.
5. Farmerie, W. G., D. D. Loeb, N. C. Casavant, C. A. Hutchison III, M. H. Edgell, and R. Swanstrom. 1987. Expression and processing of the AIDS virus reverse transcriptase in Escherichia coli. Science 236:305–308.
6. Shapiro, L., G. B. Pott, and A. H. Ralston. 2001. Alpha-1-antitrypsin inhibits human immunodeficiency virus type 1. FASEB J. 15:115–122.